Kezar Life Sciences Inc. (KZR)
6.34
0.04 (0.63%)
At close: Feb 20, 2025, 3:59 PM
6.40
0.95%
After-hours: Feb 20, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 6.3 |
| Market Cap | 46.28M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -13.12 |
| PE Ratio (ttm) | -0.48 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 6.4 |
| Volume | 33,756 |
| Avg. Volume (20D) | 43,354 |
| Open | 6.37 |
| Previous Close | 6.30 |
| Day's Range | 6.31 - 6.50 |
| 52-Week Range | 5.20 - 11.40 |
| Beta | undefined |
About KZR
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b ...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 21, 2018
Employees 58
Stock Exchange NASDAQ
Ticker Symbol KZR
Analyst Forecast
According to 2 analyst ratings, the average rating for KZR stock is "Hold." The 12-month stock price forecast is $9, which is an increase of 41.96% from the latest price.
Buy 0.00%
Hold 100.00%
Sell 0.00%
Next Earnings Release
Kezar Life Sciences Inc. is scheduled to release its earnings on Mar 13, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 months ago
+42.1%
Kezar Life Sciences shares are trading higher afte...
Unlock content with
Pro Subscription
